Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Appendix C Presentations and Visits Washington, D.C., February 15â16, 2007 ⢠Department of Energy-National Nuclear Security Administration, Office of Global Threat Reduction, Nicole Nelson-Jean, DOE-NNSA, O  ffice of North and South American Threat Reduction; Parrish Staples, DOE-NNSA, Office of Global Threat Reduction ⢠Initiatives for the Development of Commercially Viable Mo-99 Production Methods Using LEU, Roy W. Brown, Council on Radionuclides and Radiopharmaceuticals (CORAR) ⢠Conversion of Molybdenum-99 (Mo-99) Production to LEU Target Technology, Grant Malkoske, MDS-Nordion ⢠OPAL (Open Pool Australian Lightwater) Reactor and ÂMolybdenum- 99, Therese Donlevy, Australian Nuclear Science and Technology Organisa- tion (ANSTO) ⢠Mallinckrodtâs Approach to HEU to LEU Conversion, Richard A. Roberts, Tyco Health Care/Mallinckrodt ⢠The Security Imperative of Eliminating Commercial Use of HEU, Ed S. Lyman, Union of Concerned Scientists ⢠Cost of Converting from HEU to LEU Targets for Medical Radio- isotope Production, Frank von Hippel, Princeton University ⢠IAEA Input to NAS Study on Medical Radioisotope Production without HEU, Ira Goldman, International Atomic Energy Agency (IAEA) 181
182 APPENDIX C Washington, D.C., April 10â11, 2007 ⢠ANL Perspective on Conversion of Mo-99 Production from High to Low Enriched Uranium, George Vandegrift, Argonne National Labora- tory (ANL) ⢠Commercial Production of Fission Mo-99 from LEU Targets in Argentina, Pablo Cristini and Marcelo Salvatore, Comisión Nacional de Energia Atómica (CNEA) and INVAP (Investigaciones Aplicadas Sociedad del Estado) ⢠Commercial Production of Fission Radioisotopes from LEU Targets in Argentina, Pablo Cristini, CNEA ⢠FDAâs Regulatory Role in Medical Isotope Production, Orhan S  uleiman, Food and Drug Administration (FDA) ⢠NRCâs Process for Licensing Exports of Highly Enriched Uranium (HEU) Medical Isotope Target Material, Stephen Dembek, U.S. Nuclear Regulatory Commission (NRC) ⢠Highly Enriched Uranium (HEU) Exports for Medical Isotope Pro- duction, Edward T. Fei, NNSA ⢠Conversion of Molybdenum-99 (Mo-99) Production to LEU Target Technology, Grant Malkoske, MDS Nordion ⢠Mallinckrodtâs Mo-99 Process & Progress to LEU Conversion, Dale Simpson, Tyco Healthcare/Mallinckrodt ⢠Ion Beam Applications: Past, Present, and Future, Henri Bonet, Institute National des Radioéléments (IRE) Washington, D.C., June 11â12, 2007 ⢠Global Threat Reduction InitiativeâReactor Conversion Programâ Molybdenum-99 Production with LEU, Parrish Staples, DOE-NNSA ⢠Drug Master File Development and FDA Filings for LEU-Produced Medical Radionuclides, Roy Brown, CORAR ⢠Cardinal Health Nuclear Pharmacy Services, Jack Coffey, Cardinal Health ⢠The Cost of Developing Imaging Agents for Routine Clinical Use, Adrian Nunn, Bracco Research ⢠Status of IAEA Mo-99 Activities, Ira Goldman, IAEA ⢠National Academy of Sciences: Medical Isotope Production Study, Ralph Butler, University of Missouri Research Reactor (MURR) ⢠AECLâs Medical Isotope Production, Brian McGee, Atomic Energy of Canada Limited (AECL)
APPENDIX C 183 St. Louis, Missouri, October 15â17, 2007 ⢠Supporting the Nationâs Nuclear Medicine ResearchâUpdate, Ralph A. Butler, MURR ⢠Efforts by Current Commercial Mo-99 Producers to Examine LEU Technologies, Roy W. Brown, CORAR Site Visits ⢠August 20â21, 2007: Visit to AECL Chalk River Laboratories (Chalk River, Ontario, Canada) and MDS Nordion (Kanata, Ontario, Canada) ⢠December 17â18, 2007: Visit to ANSTO (Lucas Heights, Australia) ⢠March 10â12, 2008: Visit to IRE (Fleures, Belguim), CERCA (  Romans, France) and Mallinckrodt (Petten, the Netherlands) ⢠June 5â6, 2008: Visit to CNEA (Buenos Aires, Argentina)